Long-acting beta2-agonists for chronic obstructive pulmonary disease.

Area of Science:

• Respiratory Medicine
• Pharmacology
• Clinical Trials

Background:

• Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease with significant mortality and healthcare costs worldwide.
• Inhaled long-acting beta2-agonists (LABAs) are commonly prescribed for COPD symptom management when short-acting agents are insufficient.
• LABA therapy aims to relieve symptoms, enhance exercise tolerance, improve quality of life, and reduce exacerbations.

Purpose of the Study:

• To evaluate the efficacy of twice-daily inhaled long-acting beta2-agonists (LABAs) compared to placebo in patients with COPD.
• Primary endpoints included improvements in quality of life and reduction in COPD exacerbations.
• Assessment focused on clinically important outcomes for COPD management.

Main Methods:

• Systematic search of clinical trials registers and manufacturer websites up to June 2013.
• Inclusion of parallel, randomized controlled trials (RCTs) of at least 12 weeks duration comparing LABAs to placebo in COPD patients.
• Independent data extraction, bias assessment, and pooled data analysis, with subgrouping by LABA agent and trial duration.

Main Results:

• Twenty-six RCTs involving 14,939 COPD patients were analyzed.
• Moderate-quality evidence indicated LABA treatment improved quality of life (SGRQ scores) and reduced hospitalizations due to exacerbations.
• LABA therapy also decreased exacerbations requiring oral steroids/antibiotics and improved predose FEV1, with no significant effect on mortality or serious adverse events.

Conclusions:

• Inhaled LABAs demonstrate effectiveness for moderate to severe COPD over medium to long terms.
• LABA use is associated with enhanced quality of life and fewer exacerbations, including those requiring hospitalization.
• The study concluded that LABA therapy does not significantly alter mortality or the rate of serious adverse events in COPD patients.